Pathogenetic mechanisms of polycythemia vera and congenital polycythemic disorders

Seminars in Hematology

Volumn 38, Issue 1 SUPPL. 2, 2001, Pages 10-20

  Prchal, Josef T ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN RECEPTOR; CYTOKINE; CYTOKINE RECEPTOR; HEMOGLOBIN; HYPOXIA INDUCIBLE FACTOR 1; PROTEIN BCL X; SOMATOMEDIN C; THROMBOPOIETIN RECEPTOR;

ERYTHROCYTOSIS; ERYTHROPOIESIS; GENE CONTROL; GENE MUTATION; GENETIC PREDISPOSITION; HEMATOPOIESIS; HETEROZYGOSITY LOSS; METHEMOGLOBINEMIA; PATHOGENESIS; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

EID: 0035106628     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0037-1963(01)90135-0     Document Type: Review

References (107)

1. Erythropoietin (Epo) dose-response curves for three classes of erythroid progenitors in normal human marrow and in patients with polycythemia vera
2. Erythropoietin
3. The mechanism of action of erythropoietin
4. Binding and receptor-mediated endocytosis of erythropoietin in friend virus-infected erythroid cells
5. Human hematopoietic progenitors express erythropoietin
6. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation
7. The transcription factors ATF-1 and CREB-1 bind constitutively to the hypoxia-inducible factor-1 (HIF-1) DNA recognition site
8. In vivo expression of mRNAs encoding hypoxia-inducible factor 1
9. Transcriptional regulation off genes encoding glycolytic enzymes by hypoxia-inducible factor
10. Oxygen sensing and molecular adaptation to hypoxia
11. Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia
12. 2 homeostasis by hypoxia-inducible factor 1
13. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
14. HIF-1 alpha is required for solid tumor formation and embryonic vascularization
15. 2 homeostasis by hypoxia-inducible factor 1α
16. Hypoxia, clonal selection, and the role of HIF-1 in tumor progression
17. Purification and characterization of hypoxia-inducible factor 1
18. Hypoxia-inducible factor 1alpha protein expression is controlled by oxygen-regulated ubiquitination that is disrupted by deletions and missense mutations
19. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
20. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein
21. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein
22. Mechanism of regulation of the hypoxia-inducible factor-1alpha by the von Hippel-Lindau tumor suppressor protein
23. Human erythropoietin receptor: Cloning, expression, and biologic characterization
24. Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells
25. The cytoplasmic region of the erythropoietin receptor contains non-overlapping positive and negative growth-regulatory domains
26. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin
27. Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals
28. Tyrosine 343 and EPOR positively replaces EPO induced proliferation and STAT5 activation
29. Prolactin receptor and severely truncated EPORs support differentiation of erythroid progenitors
30. JAK2 is essential for signaling through a variety of cytokine receptors
31. A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors
32. Hematopoietic cell phosphatase associates with erythropoietin (Epo) receptor after Epo-induced receptor tyrosine phosphorylation: Identification of potential binding sites
33. Syp (SH-PTP2) is a positive mediator of growth factor-stimulated mitotic signal transduction
34. The erythropoietin receptor gene is not linked with polycythemia phenotype in a family with autosomal dominant primary polycythemia
35. Low frequency of erythropoietin receptor gene mutations in subjects with primary familial and congenital polycythemia
36. Erythropoietin receptor mutations and human disease
37. Production of erythropoietic bursts by progenitor cells from adult human peripheral blood in an improved serum-free medium: Role of insulin-like growth factor I
38. Circulating erythroid progenitors in polycythemia vera are hypersensitive to insulin-like growth factor I in vitro: Studies in an improved serum-free medium
39. Human erythropoiesis in vitro and the source of burst-promoting activity in a serum-free system
40. A 'serum-free' medium for the production of erythropoietic bursts by murine bone marrow cells
41. Erythropoiesis, serum erythropoietin, and IGF-I in rats during accelerated growth
42. Identification and characterization of an 8-kd peptide stimulating late erythropoiesis
43. Insulin-like growth factor binding protein-1 is elevated in patients with polycythemia vera and stimulates erythroid burst formation in vitro
44. Prolonged hypoxia induced by the reduction of maternal uterine blood flow alters insulin-like growth factor-binding protein-1 (IGFBP-1) and IGFBP-2 gene expression in the ovine fetus
45. Developmental consequences of the renin-angiotensin system
46. Angiotensin receptors: Relevance in development and disease states
47. Angiotensin II receptor-mediated proliferation of cultured human fetal mesangial cells
48. Ontogeny of the renin-angiotensin system
49. Losartan, an angiotensin II type 1 receptor antagonist, lowers hematocrit in posttransplant erythrocytosis
50. Enalapril treatment of post-transplant erythrocytosis: Efficacy independent of circulating erythropoietin levels
51. Angiotensin II stimulates proliferation of normal early erythroid progenitors
52. Direct stimulation of Jak/STAT pathway by the angiotensin II AT1 receptor
53. Congenital and Acquired Abnormality of Hemoglobin
54. Detection of mutant hemoglobins with altered affinity for oxygen. A simplified technique
55. Deficit en diphosphoglycerate mutase: Nouveaux cas associes a une polyglobulie
56. Autosomal dominant polycythemia
57. Autosomal dominant erythrocytosis causes by increased sensitivity to erythropoietin
58. Familial and congenital polycythemia in three unrelated families
59. Expression cloning of the murine erythropoietin receptor
60. The gene for the human erythropoietin receptor: Analysis of the coding sequence and assignment to chromosome 19q
61. Familial erythrocytosis genetically linked to erythropoietin receptor gene
62. Two microsatellite repeat polymorphisms in the EPO gene
63. The hyperresponsivness of cells expressing truncated EPOR in contingent upon insulin-like growth factor in fetal calf serum
64. Mouse model of congenital polycythemia: Homologous replacement of murine gene by mutant human erythropoietin receptor gene
65. Low frequency of erythropoietin receptor gene mutations in subjects with primary familial and congenital polycythemia
66. Primary familial and congenital polycythemia
67. Familial erythrocytosis among inhabitants of the Chuvash ASSR
68. Congenital polycythemia in Chuvashia
69. Putative dysregulation in the HIF-oxygen sensing pathway in congenital Chuvash polycythemia
70. Towards a molecular understanding of polycythemia rubra vera
71. Polycythemia vera stem cell and probable clonal orgin of the disease
72. Clonality in myeloproliferative disorders
73. Bone-marrow responses in polycythemia vera
74. In vitro erythropoiesis in polycythemia vera and other myeloproliferative disorders
75. Diagnostic application of haemopoietic progenitor culture technisues in polycythemia and thrombocythaemias
76. Erythroid progenitors in polycythemia vera: Demonstration of their hypersensitivity to erythropoietin using serum free cultures
77. Identification of masked polycythemia vera from patients with idiopathic marked thrombocytosis by endogenous erythroid colony assay
78. Erythroid colony formation by polycythemia vera bone marrow in vitro: Dependence on erythropoietin
79. Primary polycythemias
80. Anti-erythropoietin (EPO) receptor monoclonal antibodies distinguish EPO-dependent and EPO-independent erythroid progenitors in polycythemia
81. Two new EPO receptor mutations: Truncated EPO receptors are most frequently associated with primary familial and congenital polycythemias
82. Polycythemia vera II, hypersensitivity of bone marrow erythroid, glanulocyte-pacrophage, and megakaryocytes progenitor cells to interleukin-3 and granulocyte-macrophage colony-stimulating factor
83. Polycythemia vera blood burst forming units-erythroid are hypersensitive to interleukin-3
84. Missense mutation of the erythropoietin receptor is a rare event in human erythroid malignancies
85. Sensitivities of erythroid progenitor cells to erythropoietin (EPO) and insulin-like growth factor-1 (IGF-1) in patients with primary familial and congenital polycythemia (PFCP): Studies in strictly serum-free conditions
86. Polycythemia vera. V. Enhanced proliferation and phosphorylation due to vanadate are diminished in polycythemia vera erythroid progenitor cells: A possible defect of phosphate activity in polycythemia vera
87. Possible involvement of protein kinase C in the aberrant regulation of erythropoiesis in polycythemia vera
88. Identification of increased protein tyrosine phosphatase activity in mia vera erythroid progenitor cells
89. Protein tyrosine phosphates in signaling
90. Mutations at the murine motheaten locus are within the hematopoietic cell protein-tyrosine phosphatase (Hcph) gene
91. No evidence for an altered mRNA expression or protein level or haematopoietic cell phosphate in CD34+ bone marrow progenitor cells or mature peripheral blood cells in polycythemia vera
92. The gene encoding hematopoietic cell phophatase (SHP-1) is structurally and transcriptionally intact in polycythemia vera
93. Defective expression of the SHP-1 phosphatase in polycythemia vera
94. Markedly reduce expression of platelet c-mpl receptor in essential thrombocythemia
95. Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera
96. Expression of Bclx in erythroid precursors from patients with polycythemia vera
97. Analysis of the defective signal transduction mechanism through the platelet thromboxane A2 receptor in a patient with polycythemia vera
98. Stimulus-specific defect in platelet aggregation in polycythemia vera
99. Studies of neutrophil and monocyte oxidative responses in polycythemia vera and related myeloproliferative disorders
100. Platelet derived growth factor messenger RNA is increased in bone marrow megakaryocytes in patients with myeloproliferative disorders
101. Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera
102. Familial polycythemia vera: Mode of inheritance, clonality, and genetic analysis of candidate genes and chromosomal regions
103. Involvement of chromosome 9 and 11 in familial and sporadic polycythemia vera